How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "9155"
  ["article_id"]=>
  string(4) "9155"
  [1]=>
  string(95) "RadNet, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 10th, 2024"
  ["article_title"]=>
  string(95) "RadNet, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 10th, 2024"
  [2]=>
  string(150) "LOS ANGELES, Jan.  08, 2024  (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic i"
  ["short_description"]=>
  string(150) "LOS ANGELES, Jan.  08, 2024  (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic i"
  [3]=>
  string(573) "
LOS ANGELES, Jan.  08, 2024  (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer and Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 4:30 p.m. PST.
"
  ["description"]=>
  string(573) "
LOS ANGELES, Jan.  08, 2024  (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer and Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024 at 4:30 p.m. PST.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "26"
  ["rss_id"]=>
  string(2) "26"
  [14]=>
  string(167) "https://www.globenewswire.com/news-release/2024/01/08/2805185/10985/en/RadNet-Inc-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference-January-10th-2024.html"
  ["blog_url"]=>
  string(167) "https://www.globenewswire.com/news-release/2024/01/08/2805185/10985/en/RadNet-Inc-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference-January-10th-2024.html"
  [15]=>
  string(19) "2024-01-08 19:00:00"
  ["add_date"]=>
  string(19) "2024-01-08 19:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:29"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:29"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

RadNet, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 10th,

LOS ANGELES, Jan. 08, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader 

array(40) {
  [0]=>
  string(4) "9070"
  ["article_id"]=>
  string(4) "9070"
  [1]=>
  string(91) "Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea"
  ["article_title"]=>
  string(91) "Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea"
  [2]=>
  string(150) "SCOTTSDALE, Ariz., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company&r"
  ["short_description"]=>
  string(150) "SCOTTSDALE, Ariz., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company&r"
  [3]=>
  string(244) "SCOTTSDALE, Ariz., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and..."
  ["description"]=>
  string(244) "SCOTTSDALE, Ariz., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(44) "https://www.drugs.com/nda/dfd_29_240105.html"
  ["blog_url"]=>
  string(44) "https://www.drugs.com/nda/dfd_29_240105.html"
  [15]=>
  string(19) "2024-01-06 06:01:30"
  ["add_date"]=>
  string(19) "2024-01-06 06:01:30"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:48"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:48"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosace

SCOTTSDALE, Ariz., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical&

array(40) {
  [0]=>
  string(4) "9278"
  ["article_id"]=>
  string(4) "9278"
  [1]=>
  string(109) "Flex To Provide Advanced Manufacturing Services for Asensus Surgical’s LUNA Robotic Surgical System"
  ["article_title"]=>
  string(109) "Flex To Provide Advanced Manufacturing Services for Asensus Surgical’s LUNA Robotic Surgical System"
  [2]=>
  string(159) "“Flex’s proven track record of delivering complex electromechanical systems across diverse industries and deep understanding of the complex requir"
  ["short_description"]=>
  string(159) "“Flex’s proven track record of delivering complex electromechanical systems across diverse industries and deep understanding of the complex requir"
  [3]=>
  string(662) "
“Flex’s proven track record of delivering complex electromechanical systems across diverse industries and deep understanding of the complex requirements for medical devices will enable us to accelerate time-to-market for our LUNA platform.”
&#nl
The post Flex To Provide Advanced Manufacturing Services for Asensus Surgical’s LUNA Robotic Surgical System appeared first on MedTech Intelligence.
&#nl"
  ["description"]=>
  string(662) "
“Flex’s proven track record of delivering complex electromechanical systems across diverse industries and deep understanding of the complex requirements for medical devices will enable us to accelerate time-to-market for our LUNA platform.”
&#nl
The post Flex To Provide Advanced Manufacturing Services for Asensus Surgical’s LUNA Robotic Surgical System appeared first on MedTech Intelligence.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "98"
  ["rss_id"]=>
  string(2) "98"
  [14]=>
  string(144) "https://medtechintelligence.com/news_article/flex-to-provide-advanced-manufacturing-services-for-asensus-surgicals-luna-robotic-surgical-system/"
  ["blog_url"]=>
  string(144) "https://medtechintelligence.com/news_article/flex-to-provide-advanced-manufacturing-services-for-asensus-surgicals-luna-robotic-surgical-system/"
  [15]=>
  string(19) "2024-01-06 04:11:04"
  ["add_date"]=>
  string(19) "2024-01-06 04:11:04"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:21:30"
  ["create_at"]=>
  string(19) "2024-01-23 20:21:30"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Flex To Provide Advanced Manufacturing Services for Asensus Surgical’s LUNA Robotic

“Flex’s proven track record of delivering complex electromechanical systems across diverse industries an

array(40) {
  [0]=>
  string(4) "9102"
  ["article_id"]=>
  string(4) "9102"
  [1]=>
  string(131) "Semaglutide Associated with Lower Risk of Suicidal Ideations Compared to Other Treatments Prescribed for Obesity or Type 2 Diabetes"
  ["article_title"]=>
  string(131) "Semaglutide Associated with Lower Risk of Suicidal Ideations Compared to Other Treatments Prescribed for Obesity or Type 2 Diabetes"
  [2]=>
  string(159) "&#nlNIH-funded analysis finds patients treated with semaglutide had 49% to 73% lower risk of suicidal ideation than those given other medications.&#nl&#nlJanua"
  ["short_description"]=>
  string(159) "&#nlNIH-funded analysis finds patients treated with semaglutide had 49% to 73% lower risk of suicidal ideation than those given other medications.&#nl&#nlJanua"
  [3]=>
  string(251) "&#nlNIH-funded analysis finds patients treated with semaglutide had 49% to 73% lower risk of suicidal ideation than those given other medications.&#nl&#nlJanuary 5, 2024 -- Semaglutide, a highly popular medication approved by the U.S. Food and Drug..."
  ["description"]=>
  string(251) "&#nlNIH-funded analysis finds patients treated with semaglutide had 49% to 73% lower risk of suicidal ideation than those given other medications.&#nl&#nlJanuary 5, 2024 -- Semaglutide, a highly popular medication approved by the U.S. Food and Drug..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(142) "https://www.drugs.com/clinical_trials/semaglutide-associated-lower-risk-suicidal-ideations-compared-other-treatments-obesity-type-2-21258.html"
  ["blog_url"]=>
  string(142) "https://www.drugs.com/clinical_trials/semaglutide-associated-lower-risk-suicidal-ideations-compared-other-treatments-obesity-type-2-21258.html"
  [15]=>
  string(19) "2024-01-06 04:01:30"
  ["add_date"]=>
  string(19) "2024-01-06 04:01:30"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:50"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:50"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Semaglutide Associated with Lower Risk of Suicidal Ideations Compared to Other Treatments

&#nlNIH-funded analysis finds patients treated with semaglutide had 49% to 73% lower risk of suicidal ideation than thos

array(40) {
  [0]=>
  string(4) "9243"
  ["article_id"]=>
  string(4) "9243"
  [1]=>
  string(49) "AI and public health – a major opportunity"
  ["article_title"]=>
  string(49) "AI and public health – a major opportunity"
  [2]=>
  string(158) ""The intersection of public health and artificial intelligence represents a transformation in healthcare," says one epidemiologist, who sees the chanc"
  ["short_description"]=>
  string(158) ""The intersection of public health and artificial intelligence represents a transformation in healthcare," says one epidemiologist, who sees the chanc"
  [3]=>
  string(250) ""The intersection of public health and artificial intelligence represents a transformation in healthcare," says one epidemiologist, who sees the chance to greatly improve disease prevention and management, and promote health and wellness.&#nl"
  ["description"]=>
  string(250) ""The intersection of public health and artificial intelligence represents a transformation in healthcare," says one epidemiologist, who sees the chance to greatly improve disease prevention and management, and promote health and wellness.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(76) "https://www.healthcareitnews.com/news/ai-and-public-health-major-opportunity"
  ["blog_url"]=>
  string(76) "https://www.healthcareitnews.com/news/ai-and-public-health-major-opportunity"
  [15]=>
  string(19) "2024-01-06 01:24:31"
  ["add_date"]=>
  string(19) "2024-01-06 01:24:31"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

AI and public health – a major opportunity

"The intersection of public health and artificial intelligence represents a transformation in healthcare," says 

array(40) {
  [0]=>
  string(4) "9244"
  ["article_id"]=>
  string(4) "9244"
  [1]=>
  string(65) "ONC info blocking disincentives are 'excessive,' says AHA"
  ["article_title"]=>
  string(65) "ONC info blocking disincentives are 'excessive,' says AHA"
  [2]=>
  string(154) "The American Hospital Association questions the agency's calculations, and said the proposed information blocking penalties could threaten the financi"
  ["short_description"]=>
  string(154) "The American Hospital Association questions the agency's calculations, and said the proposed information blocking penalties could threaten the financi"
  [3]=>
  string(205) "The American Hospital Association questions the agency's calculations, and said the proposed information blocking penalties could threaten the financial viability of many small and rural hospitals.&#nl"
  ["description"]=>
  string(205) "The American Hospital Association questions the agency's calculations, and said the proposed information blocking penalties could threaten the financial viability of many small and rural hospitals.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(92) "https://www.healthcareitnews.com/news/onc-info-blocking-disincentives-are-excessive-says-aha"
  ["blog_url"]=>
  string(92) "https://www.healthcareitnews.com/news/onc-info-blocking-disincentives-are-excessive-says-aha"
  [15]=>
  string(19) "2024-01-05 23:56:22"
  ["add_date"]=>
  string(19) "2024-01-05 23:56:22"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

ONC info blocking disincentives are 'excessive,' says AHA

The American Hospital Association questions the agency's calculations, and said the proposed information blocking pe

array(40) {
  [0]=>
  string(4) "9044"
  ["article_id"]=>
  string(4) "9044"
  [1]=>
  string(154) "Leiters Health Issues Voluntary Nationwide Recall of Vancomycin IV Bags, Phenylephrine IV Bags, and Fentanyl IV Bags Due to Potential for Superpotent Drug"
  ["article_title"]=>
  string(154) "Leiters Health Issues Voluntary Nationwide Recall of Vancomycin IV Bags, Phenylephrine IV Bags, and Fentanyl IV Bags Due to Potential for Superpotent Drug"
  [2]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy January 5, 2024 – Englewood, Colorado, Leiters Health is voluntarily recalling 33 lots of prod"
  ["short_description"]=>
  string(150) "Audience: Consumer, Health Professional, Pharmacy January 5, 2024 – Englewood, Colorado, Leiters Health is voluntarily recalling 33 lots of prod"
  [3]=>
  string(250) "Audience: Consumer, Health Professional, Pharmacy January 5, 2024 – Englewood, Colorado, Leiters Health is voluntarily recalling 33 lots of products listed below to the user level. The recalled batches of vancomycin IV bags, phenylephrine IV..."
  ["description"]=>
  string(250) "Audience: Consumer, Health Professional, Pharmacy January 5, 2024 – Englewood, Colorado, Leiters Health is voluntarily recalling 33 lots of products listed below to the user level. The recalled batches of vancomycin IV bags, phenylephrine IV..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "7"
  ["rss_id"]=>
  string(1) "7"
  [14]=>
  string(136) "https://www.drugs.com/fda/leiters-health-issues-voluntary-nationwide-recall-vancomycin-iv-bags-phenylephrine-iv-bags-fentanyl-14648.html"
  ["blog_url"]=>
  string(136) "https://www.drugs.com/fda/leiters-health-issues-voluntary-nationwide-recall-vancomycin-iv-bags-phenylephrine-iv-bags-fentanyl-14648.html"
  [15]=>
  string(19) "2024-01-05 21:03:00"
  ["add_date"]=>
  string(19) "2024-01-05 21:03:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Leiters Health Issues Voluntary Nationwide Recall of Vancomycin IV Bags, Phenylephrine IV

Audience: Consumer, Health Professional, Pharmacy January 5, 2024 – Englewood, Colorado, Leiters Health is volunta

array(40) {
  [0]=>
  string(4) "9062"
  ["article_id"]=>
  string(4) "9062"
  [1]=>
  string(89) "FDA Approves Zelsuvmi (berdazimer topical gel) for the Treatment of Molluscum Contagiosum"
  ["article_title"]=>
  string(89) "FDA Approves Zelsuvmi (berdazimer topical gel) for the Treatment of Molluscum Contagiosum"
  [2]=>
  string(150) "SAN DIEGO--(BUSINESS WIRE) January 5, 2024 --  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administ"
  ["short_description"]=>
  string(150) "SAN DIEGO--(BUSINESS WIRE) January 5, 2024 --  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administ"
  [3]=>
  string(247) "SAN DIEGO--(BUSINESS WIRE) January 5, 2024 --  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved Zelsuvmi™ (berdazimer topical gel, 10.3%) for the treatment of..."
  ["description"]=>
  string(247) "SAN DIEGO--(BUSINESS WIRE) January 5, 2024 --  Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved Zelsuvmi™ (berdazimer topical gel, 10.3%) for the treatment of..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(107) "https://www.drugs.com/newdrugs/fda-approves-zelsuvmi-berdazimer-topical-gel-molluscum-contagiosum-6180.html"
  ["blog_url"]=>
  string(107) "https://www.drugs.com/newdrugs/fda-approves-zelsuvmi-berdazimer-topical-gel-molluscum-contagiosum-6180.html"
  [15]=>
  string(19) "2024-01-05 08:01:41"
  ["add_date"]=>
  string(19) "2024-01-05 08:01:41"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:19:47"
  ["create_at"]=>
  string(19) "2024-01-23 20:19:47"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Approves Zelsuvmi (berdazimer topical gel) for the Treatment of Molluscum Contagiosum

SAN DIEGO--(BUSINESS WIRE) January 5, 2024 -- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that t

array(40) {
  [0]=>
  string(4) "9245"
  ["article_id"]=>
  string(4) "9245"
  [1]=>
  string(61) "AI in 2024: Welcome to the 'new normal' in healthcare"
  ["article_title"]=>
  string(61) "AI in 2024: Welcome to the 'new normal' in healthcare"
  [2]=>
  string(150) "Regulators are starting to see an opportunity to incentivize the use of artificial intelligence and machine learning, says one expert, who predicts ac"
  ["short_description"]=>
  string(150) "Regulators are starting to see an opportunity to incentivize the use of artificial intelligence and machine learning, says one expert, who predicts ac"
  [3]=>
  string(229) "Regulators are starting to see an opportunity to incentivize the use of artificial intelligence and machine learning, says one expert, who predicts accelerating adoption ahead, with "meaningful use" of explainable AI.&#nl"
  ["description"]=>
  string(229) "Regulators are starting to see an opportunity to incentivize the use of artificial intelligence and machine learning, says one expert, who predicts accelerating adoption ahead, with "meaningful use" of explainable AI.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(75) "https://www.healthcareitnews.com/news/ai-2024-welcome-new-normal-healthcare"
  ["blog_url"]=>
  string(75) "https://www.healthcareitnews.com/news/ai-2024-welcome-new-normal-healthcare"
  [15]=>
  string(19) "2024-01-05 01:45:13"
  ["add_date"]=>
  string(19) "2024-01-05 01:45:13"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

AI in 2024: Welcome to the 'new normal' in healthcare

Regulators are starting to see an opportunity to incentivize the use of artificial intelligence and machine learning, sa

array(40) {
  [0]=>
  string(4) "9159"
  ["article_id"]=>
  string(4) "9159"
  [1]=>
  string(75) "Crossject engages Syneos Health for  U.S. commercial launch of ZEPIZURE®"
  ["article_title"]=>
  string(75) "Crossject engages Syneos Health for  U.S. commercial launch of ZEPIZURE®"
  [2]=>
  string(13) "Press Release"
  ["short_description"]=>
  string(13) "Press Release"
  [3]=>
  string(37) "
Press Release
"
  ["description"]=>
  string(37) "
Press Release
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(141) "https://www.globenewswire.com/news-release/2024/01/04/2804220/0/en/Crossject-engages-Syneos-Health-for-U-S-commercial-launch-of-ZEPIZURE.html"
  ["blog_url"]=>
  string(141) "https://www.globenewswire.com/news-release/2024/01/04/2804220/0/en/Crossject-engages-Syneos-Health-for-U-S-commercial-launch-of-ZEPIZURE.html"
  [15]=>
  string(19) "2024-01-05 01:00:00"
  ["add_date"]=>
  string(19) "2024-01-05 01:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:30"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:30"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®

Press Release

array(40) {
  [0]=>
  string(4) "9160"
  ["article_id"]=>
  string(4) "9160"
  [1]=>
  string(94) "Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-Unis"
  ["article_title"]=>
  string(94) "Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-Unis"
  [2]=>
  string(23) "Communiqué de presse"
  ["short_description"]=>
  string(23) "Communiqué de presse"
  [3]=>
  string(47) "
Communiqué de presse
"
  ["description"]=>
  string(47) "
Communiqué de presse
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(163) "https://www.globenewswire.com/news-release/2024/01/04/2804220/0/fr/Crossject-engage-Syneos-Health-pour-le-lancement-commercial-du-ZEPIZURE-aux-%C3%89tats-Unis.html"
  ["blog_url"]=>
  string(163) "https://www.globenewswire.com/news-release/2024/01/04/2804220/0/fr/Crossject-engage-Syneos-Health-pour-le-lancement-commercial-du-ZEPIZURE-aux-%C3%89tats-Unis.html"
  [15]=>
  string(19) "2024-01-05 01:00:00"
  ["add_date"]=>
  string(19) "2024-01-05 01:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:30"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:30"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-

Communiqué de presse

array(40) {
  [0]=>
  string(4) "9246"
  ["article_id"]=>
  string(4) "9246"
  [1]=>
  string(53) "Penn Medicine develops AI tool for precision oncology"
  ["article_title"]=>
  string(53) "Penn Medicine develops AI tool for precision oncology"
  [2]=>
  string(150) "The application, known as iStar, was created by Perelman School of Medicine researchers to give clinicians more insights into gene activities in medic"
  ["short_description"]=>
  string(150) "The application, known as iStar, was created by Perelman School of Medicine researchers to give clinicians more insights into gene activities in medic"
  [3]=>
  string(251) "The application, known as iStar, was created by Perelman School of Medicine researchers to give clinicians more insights into gene activities in medical images and, potentially, help them diagnose cancers that might have otherwise been undetected.&#nl"
  ["description"]=>
  string(251) "The application, known as iStar, was created by Perelman School of Medicine researchers to give clinicians more insights into gene activities in medical images and, potentially, help them diagnose cancers that might have otherwise been undetected.&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "57"
  ["rss_id"]=>
  string(2) "57"
  [14]=>
  string(87) "https://www.healthcareitnews.com/news/penn-medicine-develops-ai-tool-precision-oncology"
  ["blog_url"]=>
  string(87) "https://www.healthcareitnews.com/news/penn-medicine-develops-ai-tool-precision-oncology"
  [15]=>
  string(19) "2024-01-05 00:00:53"
  ["add_date"]=>
  string(19) "2024-01-05 00:00:53"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-01-23 20:20:53"
  ["create_at"]=>
  string(19) "2024-01-23 20:20:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Penn Medicine develops AI tool for precision oncology

The application, known as iStar, was created by Perelman School of Medicine researchers to give clinicians more insights